PamGene

PamGene is a Dutch biotechnology company founded in 2000 and headquartered in 's-Hertogenbosch (Den Bosch), the Netherlands. The company has developed a microarray-based technology for multiplex kinase activity profiling, which measures the activity of many kinases simultaneously to reveal a broader picture of cellular signaling. This functional profiling approach is positioned as a way to gain mechanistic insight into diseases and cellular alterations, complementing genomic and proteomic methods. PamGene serves three main customer groups: diagnostics, pharma & biotech, and science. In diagnostics, the company focuses on immuno-oncology, where its kinase activity profiling is used to support treatment and development optimization through patient stratification. For pharma and biotech customers, PamGene offers services to discover, optimize and analyze therapeutic kinase inhibitor candidates and their mechanisms of action. For scientific researchers, the company provides 'kinome' and mechanistic insights into biological models. The company markets its capabilities under the PamDx name, describing itself as dedicated to supporting physicians and scientists in finding solutions and answers to improve and optimize patient treatment and understand diseases. Its core offering is a robust and unique microarray technology for multiplex kinase activity profiling, together with dedicated assay services for biomarker discovery, patient stratification and therapy selection for oncological diseases. PamGene operates internationally from its Dutch base and presents itself as an organization active at the cutting edge of high-tech and biology, with an informal, no-nonsense team culture.

PamGene was founded in 2000 as a Dutch biotechnology company and established its headquarters in 's-Hertogenbosch (Den Bosch), the Netherlands. From its base in the Dutch life-sciences ecosystem, the company developed a microarray-based platform for multiplex kinase activity profiling, a functional approach that measures the activity of many kinases at once rather than merely their abundance or sequence. Over the years, PamGene built its business around applying this technology to three customer segments: diagnostics, pharma & biotech, and science. In diagnostics, the company concentrated on immuno-oncology, using kinase activity profiling to support treatment and development optimization through patient stratification. For pharmaceutical and biotechnology customers, it offered services to discover, optimize and analyze therapeutic kinase inhibitor candidates and their mechanisms of action. For scientific customers, it provided kinome and mechanistic insights into biological models. The company has marketed its capabilities under the PamDx name, describing itself as dedicated to supporting physicians and scientists in improving and optimizing patient treatment and understanding diseases. Its stated core asset is a robust and unique microarray technology for multiplex kinase activity profiling, complemented by dedicated assay services for biomarker discovery, patient stratification and therapy selection for oncological diseases. PamGene presents itself as an internationally operating organization active at the cutting edge of high-tech and biology, with an informal, no-nonsense team culture, and it continues to recruit for roles such as Senior Business Developer Manager Diagnostics (Europe) to support commercial growth in cancer diagnostics.

• 2000

  PamGene founded as a Dutch biotechnology company.

• Headquarters established in 's-Hertogenbosch (Den Bosch), the Netherlands.

• Developed microarray technology for multiplex kinase activity profiling.

• Marketed capabilities under the PamDx name for diagnostics, pharma & biotech, and science customers.

Provider of multiplex, functional kinase activity profiling technology and assay services that reveal the bigger picture of cellular signaling for diagnostics, pharma & biotech, and science customers.

• Multiplex kinase activity profiling microarray technology

  A robust and unique microarray platform that measures the activity of many kinases simultaneously to reveal cellular signaling.

• Assay services for biomarker discovery, patient stratification and therapy selection

  Dedicated assay services for oncological diseases, supporting diagnostics and drug development.

1. 1PamDx – Digital Solutions & Innovative Technologypamdx.com
2. 2About us - PamDxpamdx.com
3. 3Career - PamDxpamdx.com
4. 4Advisors - PamDxpamdx.com
5. 5PamGene (Netherlands) - Wikidatawikidata.org